influenza
viru
still
major
caus
diseas
human
account
three
five
million
case
sever
ill
death
year
effici
influenza
vaccin
avail
induc
antibodi
predominantli
two
major
compon
viru
membran
hemagglutinin
ha
neuramidas
na
protect
mediat
primarili
neutral
antibodi
ha
sinc
ha
undergo
continu
chang
due
mutat
antigen
drift
new
antigen
variant
influenza
aris
everi
year
requir
constant
updat
vaccin
effect
vaccin
complic
occasion
reassort
segment
viral
genom
lead
replac
ha
na
one
subtyp
anoth
subtyp
processs
call
antigen
shift
passiv
immun
monoclon
antibodi
mab
target
ha
effici
howev
suffer
disadvantag
current
vaccin
due
antigen
shift
drift
ideal
target
activ
passiv
immun
strategi
would
therefor
conserv
viral
protein
matrix
protein
fit
bill
receiv
consider
attent
potenti
target
influenza
infect
past
decad
tetramer
ion
channel
involv
viru
uncoat
endosom
viru
matur
transgolgi
network
amino
acid
extracellular
domain
remain
remark
conserv
human
influenza
viru
isol
last
hundr
year
least
part
due
fact
protein
cotranscrib
matrix
protein
wherea
abundantli
express
infect
cell
molecul
present
influenza
viru
membran
accord
current
season
influenza
vaccin
induc
signific
humor
resons
specif
antibodi
administ
intraven
induc
activ
immun
mediat
protect
neutral
virion
elimin
infect
cell
adcc
passiv
immun
monoclon
antibodi
sever
advantag
vaccin
particular
allow
treat
peopl
poorli
respond
vaccin
elderli
young
children
immun
compromis
individu
addit
passiv
immunis
treatment
option
choic
situat
rapid
protect
crucial
postexposur
treatment
prophylaxi
acut
expos
number
ectodomain
specif
mab
report
protect
mice
lethal
challeng
prophylact
set
mab
includ
fulli
human
antibodi
deriv
transchromosom
mice
natur
human
antibodi
report
date
howev
applic
human
subject
natur
human
antibodi
prefer
choic
contrast
human
fulli
human
antibodi
deriv
phage
display
transchromosom
mice
natur
human
antibodi
combin
advantag
minim
immunogen
smallest
possibl
offtarget
reactiv
toxic
furthermor
human
deriv
antibodi
advantag
gone
affin
matur
process
result
high
affin
antibodi
recent
describ
novel
method
effici
isol
antibodi
human
mammalian
cell
display
use
method
isol
natur
human
antibodi
direct
demonstr
antibodi
bind
high
affin
effici
recogn
recent
isol
influenza
strain
antibodi
potent
prophylact
activ
mous
model
influenzi
infect
also
show
efficaci
therapeut
set
thu
natur
human
antibodi
describ
potenti
immunotherapeut
influenza
infect
human
mab
isol
sindbismedi
mammalian
cell
display
first
b
cell
isol
fac
peripher
blood
mononuclear
cell
pbmc
individu
high
titer
use
consensu
peptid
tabl
conjug
viruslik
particl
bait
immunoglobulin
variabl
region
vr
heavi
chain
hc
light
chain
lc
amplifi
rtpcr
assembl
singlechain
antibodi
scfv
code
region
two
separ
librari
one
encod
scfv
antibodi
lcvr
clone
sindbi
cell
surfac
display
vector
pdelsptm
result
sublibrari
consist
independ
transform
respect
sinc
librari
deriv
cell
may
expect
everi
possibl
combin
heavi
light
chain
cover
multipl
time
million
clone
accordingli
screen
like
yield
antibodi
contain
natur
heavi
light
chain
pair
recombin
sindbi
viru
librari
gener
titer
pfuml
pfuml
respect
use
infect
bhk
cell
low
multipl
infect
moi
ascertain
express
singl
antibodi
speci
per
infect
cell
cell
stain
cell
surfac
express
scfv
use
conjug
subject
fac
antibodi
could
found
surfac
bhk
cell
infect
sublibrari
contrast
bhk
cell
infect
sublibrari
contain
substanti
fraction
cell
typic
infect
cell
three
sort
carri
librari
two
use
shown
one
use
bait
figur
lead
isol
bhk
cell
display
antibodi
singl
cell
sort
well
contain
bhk
feeder
cell
incub
day
allow
amplif
correspond
sindbi
viru
clone
total
well
show
sign
viral
infect
reanalyz
bind
use
bait
figur
cell
show
vari
degre
bind
identifi
supernat
well
contain
infect
bhk
cell
display
highli
scfv
use
clone
correspond
scfv
code
region
rtpcr
larg
number
specif
antibodi
isol
singl
screen
illustr
util
mammalian
cell
display
also
make
attract
altern
method
typic
base
clone
antibodi
singl
amplifi
b
cell
clone
ebvimmort
memori
b
cell
sinc
protect
potenti
antibodi
depend
adcc
scfv
antibodi
fuse
fc
region
mous
allow
vivo
efficaci
test
mous
model
influenza
fusion
protein
express
hek
cell
use
epstein
barr
viru
ebv
base
episom
express
vector
bind
antibodi
confirm
elisa
use
supernat
transient
transfect
cell
shown
clone
select
analysi
express
cell
purifi
affin
chromatographi
three
antibodi
express
high
level
yield
mg
per
liter
yield
rang
one
previous
report
nicotinespecif
human
antibodi
demonstr
mammalian
cell
display
method
consist
yield
antibodi
highli
express
mammalian
cell
next
determin
affin
end
dissoci
constant
kd
antibodi
bind
solut
determin
use
elisabas
method
figur
antibodi
found
bind
peptid
high
affin
kd
valu
nm
figur
next
set
experi
abil
antibodi
crossreact
peptid
cover
recent
influenza
isol
assess
elisa
sequenc
peptid
use
coat
shown
tabl
thu
elisa
plate
coat
peptid
conjug
rnase
serial
dilut
differ
antibodi
appli
significantli
antibodi
bound
peptid
similar
extent
valu
ngml
pm
indic
effici
crossreact
final
bind
antibodi
nativ
cell
surfac
investig
figur
end
clone
cell
express
fulllength
deriv
influenza
gener
sequenc
extracellular
domain
shown
tabl
cell
stain
increas
concentr
concentrationdepend
stain
cell
observ
demonstr
antibodi
capabl
recogn
cellular
nativ
protein
agreement
elisa
result
three
antibodi
show
similar
bind
cell
express
next
explor
clinic
potenti
antibodi
investig
protect
activ
vivo
model
influenza
infect
model
reflect
aspect
influenza
infect
human
therefor
routin
use
assess
efficaci
antivir
agent
group
mice
passiv
immun
ip
antibodi
control
group
receiv
amount
mous
igg
two
day
later
anim
infect
intranas
lethal
dose
mous
adapt
influenza
monitor
morbid
mortal
figur
control
mice
treat
mous
igg
show
dramat
drop
bodi
temperatur
substanti
weight
loss
within
day
infect
euthan
day
due
sever
symptom
figur
contrast
anim
treat
antibodi
surviv
lethal
challeng
hardli
develop
fever
display
transient
weight
loss
figur
next
set
determin
amount
antibodi
requir
achiev
protect
prophylact
set
mice
end
group
mice
treat
decreas
amount
control
mous
igg
two
day
later
anim
infect
lethal
dose
influenza
monitor
day
figur
expect
control
mice
quickli
succumb
infect
euthan
due
sever
diseas
within
less
two
week
challeng
contrast
anim
receiv
least
antibodi
surviv
challeng
even
lowest
dose
half
mice
recov
surviv
infect
indic
antibodi
potent
prophylact
agent
view
potent
prophylact
activ
antibodi
abil
control
establish
viral
infect
test
next
figur
thu
group
mice
infect
lethal
dose
influenza
treat
singl
inject
day
challeng
anim
treat
mous
igg
two
day
prior
infect
serv
posit
neg
control
respect
accord
result
mice
treat
control
antibodi
succumb
diseas
wherea
mice
receiv
antibodi
prophylact
surviv
lethal
challeng
importantli
almost
anim
treat
therapeut
within
two
day
infect
surviv
challeng
even
anim
treat
day
post
infect
appear
withstand
infect
longer
control
group
recent
human
antibodi
report
show
therapeut
activ
mice
howev
multipl
inject
start
earli
h
infect
requir
full
protect
antibodi
compar
favor
sinc
fulli
protect
singl
inject
day
still
show
protect
administ
day
challeng
taken
togeth
data
indic
treatment
antibodi
addit
potenti
preexposur
prophylaxi
may
also
use
therapeut
earli
stage
infect
given
intend
use
antibodi
human
produc
fulli
human
cell
use
ebvbas
episom
express
system
similar
antibodi
express
high
level
mammalian
cell
yield
approxim
mg
per
liter
cultur
supernat
evalu
protect
activ
influenza
mous
model
compar
counterpart
thu
group
mice
treat
equimolar
amount
human
igg
two
day
later
anim
infect
lethal
dose
influenza
closli
monitor
day
figur
mice
treat
control
human
igg
display
dramat
drop
bodi
temperatur
weight
loss
euthan
day
infect
due
sever
symptom
contrast
anim
treat
antibodi
surviv
lethal
challeng
hardli
experienc
fever
show
transient
drop
bodi
weight
thu
protect
fusion
protein
fulli
human
indic
human
antibodi
abl
recruit
effector
function
mous
system
may
use
valuabl
prophylact
therapeut
agent
human
human
antibodi
specif
influenza
protein
isol
shown
potent
prophylact
therapeut
activ
mous
model
underscor
util
sindbisbas
mammalian
cell
display
isol
natur
human
antibodi
therapeut
potenti
peripher
blood
mononuclear
cell
pbmc
isol
ml
heparin
blood
ficol
gradient
pbmc
preincub
alexa
nmlabel
human
gamma
globulin
jackson
immunoresearch
stain
coupl
combin
alexa
nmlabel
mous
mab
well
mous
mab
abcam
combin
fitclabel
donkey
antimous
igg
antibodi
jackson
immunoresearch
pelabel
mous
antihuman
igm
mous
antihuman
igd
mous
antihuman
mous
antihuman
antibodi
bd
biosciencespharmingen
petexasredlabel
mous
antihuman
antibodi
caltag
laboratori
stain
cell
wash
filter
b
cell
sort
se
flow
cytomet
becton
dickinson
sindbi
virusbas
scfv
cell
surfac
display
librari
produc
antigenspecif
b
cell
describ
bhk
cell
infect
sindbi
librari
cell
display
scfv
antibodi
isol
use
coupl
rnase
combin
rnasespecif
rabbit
polyclon
antibodi
abcam
fitclabel
donkey
antirabbit
igg
antibodi
jackson
immunoresearch
altern
cell
display
scfv
antibodi
isol
use
combin
mous
mab
abcam
fitclabel
donkey
antimous
igg
antibodi
jackson
immunoresearch
cell
sort
well
plate
contain
confluent
bhk
feeder
cell
upon
viru
spread
day
post
sort
infect
cell
test
fac
analysi
identifi
viru
clone
encod
scfv
antibodi
fusion
protein
gener
carri
ntermin
human
scfv
fuse
ctermin
mous
domain
thu
scfv
code
region
pcr
amplifi
sindbi
viruscontain
supernat
rtpcr
digest
restrict
endonucleas
clone
express
vector
vector
deriv
episom
mammalian
express
vector
invitrogen
carri
epsteinbarr
viru
replic
origin
orip
nuclear
antigen
encod
gene
permit
extrachromosom
replic
contain
puromycin
select
marker
place
origin
hygromycin
b
resist
gene
result
plasmid
drive
express
fusion
protein
control
cmv
promot
fulli
human
heavi
chain
light
chain
code
region
gener
total
gene
synthesi
geneart
ag
regensburg
germani
combin
ebnabas
express
vector
essenti
describ
express
fusion
protein
well
fulli
human
antibodi
done
transfect
express
vector
cell
use
lipofectamin
plu
invitrogen
larg
scale
product
purif
stabl
proteinexpress
cell
enrich
select
presenc
puromycin
sigma
pool
resist
cell
maintain
serumfre
medium
polyllysin
coat
dish
roller
bottl
week
supernat
contain
respect
antibodi
collect
twice
week
filter
millex
gv
steril
filter
millipor
type
antibodi
purifi
affin
chromatographi
protein
asepharos
column
ge
healthcar
elisa
plate
well
maxisorb
nunc
coat
concentr
coat
buffer
ph
one
hour
plate
wash
wash
buffer
tween
block
h
bsa
wash
buffer
plate
wash
incub
serial
dilut
wash
buffer
contain
bsa
plate
incub
h
room
temperatur
extens
wash
wash
buffer
specif
bound
antibodi
detect
hrpolabel
goat
antimous
igg
antibodi
jackson
immunoresearch
laboratori
extens
wash
wash
buffer
plate
develop
mgml
solut
dihydrochlorid
opd
citric
acid
buffer
mm
citric
acid
mm
ph
contain
min
reaction
stop
solut
plate
read
nm
elisa
reader
biorad
benchmark
ngml
solut
respect
incub
presenc
differ
concentr
peptid
serial
dilut
correspond
nm
pm
bsa
h
room
temperatur
free
antibodi
detect
classic
elisa
similar
one
describ
elisa
plate
coat
conjug
concentr
ngml
overnight
wash
wash
buffer
tween
block
h
bsa
wash
buffer
plate
wash
incub
solut
bind
reaction
min
room
temperatur
extens
wash
wash
buffer
bound
fusion
protein
detect
h
incub
room
temperatur
hrpolabel
goat
antimous
igg
antibodi
jackson
immunoresearch
laboratori
extens
wash
wash
buffer
plate
develop
describ
kd
valu
determin
elisa
signal
function
peptid
concentr
present
solut
bind
reaction
prophylact
therapeut
activ
antibodi
test
mous
model
influenza
infect
thu
six
week
old
femal
mice
per
group
infect
intranas
lethal
dose
mouseadapt
influenza
viru
follow
close
monitor
weightloss
fever
twice
daili
peak
infect
antibodi
inject
intraperiton
either
day
prophylact
set
day
infect
therapeut
set
one
day
later
mice
bled
order
verifi
presenc
antibodi
blood
elisa
shown
antibodi
readili
detect
sera
mice
except
one
mous
receiv
figur
one
mous
receiv
figur
mice
subsequ
remov
analysi
anim
experi
carri
accord
protocol
approv
swiss
feder
veterinari
offic
anim
whose
bodi
temperatur
reach
consid
moribund
euthan
immedi
due
abort
criteria
defin
veterinari
offic
author
present
former
employe
cyto
biotechnolog
ag
hold
stock
stock
option
compani
author
addit
financi
interest
rrb
mb
ns
war
ps
mfb
design
research
rrb
mb
rbb
mg
sm
perform
research
rrb
mb
ns
war
ps
mfb
analyz
data
rrb
wrote
paper
author
read
approv
final
manuscript
